177Lu-prostate-specific membrane antigen-617 (177Lu-PSMA-617) is a radioligand therapy that targets prostate-specific membrane antigen (PSMA), a receptor highly expressed on prostate cancer cells (1). The gene discussed is FOLH1; the disease is prostate carcinoma.